Literature DB >> 7746412

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.

M A Pavol1, C A Meyers, J L Rexer, A D Valentine, P J Mattis, M Talpaz.   

Abstract

We evaluated the neuropsychological and personality profiles of 25 patients with chronic myelogenous leukemia treated with interferon alfa (IFN-alpha). This group of persons performed well below expectation on tests of cognitive speed, verbal memory, and executive functions. Personality changes included depression, increased somatic concern, and stress reactions. A control group of leukemia patients not treated with IFN-alpha had significantly better cognitive speed and mood. The pattern of cognitive and personality changes in patients receiving IFN-alpha is highly suggestive of frontal-subcortical brain dysfunction.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7746412     DOI： 10.1212/wnl.45.5.947

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  30 in total

1.  Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis.

Authors:  Maiko Moriyama; Takeshi Fukuhara; Markus Britschgi; Yingbo He; Ramya Narasimhan; Saul Villeda; Hector Molina; Brigitte T Huber; Mike Holers; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

2.  What can post-mortem studies tell us about the pathoetiology of suicide?

Authors:  Ghanshyam N Pandey; Yogesh Dwivedi
Journal:  Future Neurol       Date:  2010-09

3.  Cognitive impairment in hepatitis C patients on antiviral therapy.

Authors:  Jessica Irwin; Norah Terrault
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

Review 4.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

5.  Anterior cingulate activation and error processing during interferon-alpha treatment.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Marina Demetrashvili; Bobbi J Woolwine; Charles B Nemeroff; Gregory S Berns; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2005-08-01       Impact factor: 13.382

6.  Behavioral evaluation of transgenic mice with CNS expression of IFN-alpha by elevated plus-maze and Porsolt swim test.

Authors:  Hua Zhang; Zhanzhuang Tian; Jianping Wang
Journal:  Neurosci Lett       Date:  2010-06-04       Impact factor: 3.046

7.  Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

Authors:  Lisa A Hammond-Thelin; Melanie B Thomas; Michiko Iwasaki; James L Abbruzzese; Yvonne Lassere; Christina A Meyers; Paulo Hoff; Johann de Bono; Jody Norris; Hitoshi Matsushita; Akira Mita; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2010-09-14       Impact factor: 3.850

8.  Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Maria Cecilia G Marcondes; Claudia Flynn; Salvador Huitron-Rezendiz; Debbie D Watry; Michelle Zandonatti; Howard S Fox
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

9.  The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer.

Authors:  Barry J Laird; Donald C McMillan; Peter Fayers; Kenneth Fearon; Stein Kaasa; Marie T Fallon; Pål Klepstad
Journal:  Oncologist       Date:  2013-08-21

10.  Depression following pegylated interferon-alpha: characteristics and vulnerability.

Authors:  Francis E Lotrich; Mordechai Rabinovitz; Patricia Gironda; Bruce G Pollock
Journal:  J Psychosom Res       Date:  2007-08       Impact factor: 3.006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.